Study Summary
This trial will study if a new drug is effective, safe, and well tolerated in people with ASD aged 15-45 years.
- Pervasive Development Disorders
- Autoimmune Diseases
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: Days 14, 42, 84, 98, 126
Trial Safety
Safety Progress
Side Effects for
Trial Design
3 Treatment Groups
RO7017773 Low Dose
1 of 3
RO7017773 High Dose
1 of 3
Placebo
1 of 3
Experimental Treatment
Non-Treatment Group
105 Total Participants · 3 Treatment Groups
Primary Treatment: RO7017773 · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age < 65 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 1st, 2021
Last Reviewed: November 18th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| New York | 35.7% |
| Illinois | 17.9% |
| Arizona | 17.9% |
| Other | 28.6% |
How old are they?
| < 18 | 50.0% |
| 18 - 65 | 46.4% |
| 65+ | 3.6% |
What site did they apply to?
| Southwest Autism Research & Resource Center | 36.8% |
| Montefiore Medical Center | 21.1% |
| A.O.U. Policlinico - V. Emanuele - P.O. Gaspare Rodolico; Dip. Terapia integrata disturbi resistenti | 15.8% |
| Other | 26.3% |
What portion of applicants met pre-screening criteria?
| Met criteria | 67.9% |
| Did not meet criteria | 32.1% |